Baudax Bio, Inc. - $BXRX STOCK NEWS

Welcome to our dedicated page for Baudax Bio news (Ticker: $BXRX), a resource for investors and traders seeking the latest updates and insights on Baudax Bio stock.

Baudax Bio, Inc. (NASDAQ: BXRX) is a specialized pharmaceutical company focused on developing and commercializing innovative products designed to meet the needs of hospital and acute care settings. The company's lead product candidate is an intravenous form of meloxicam, a non-opioid analgesic that has completed Phase III clinical trials for the management of moderate to severe pain. Current research includes Phase IIIB clinical trials aiming to assess opioid consumption, pain intensity, and the length of hospital stay in colorectal and orthopedic surgery patients. These trials also evaluate various pharmacoeconomic parameters.

Beyond meloxicam, Baudax Bio is advancing a pipeline of early-stage product candidates including RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) in Phase I clinical trials, and RP2000, an ultra-short-acting NMBA currently in pre-clinical trials. The company is also developing a reversal agent for these NMBAs and DEX-IN, a proprietary intranasal formulation of dexmedetomidine.

Recently, Baudax Bio announced that the U.S. FDA has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors. TI-168 is a next-generation Treg therapy designed to address Hemophilia A patients with FVIII inhibitors effectively.

Founded in 2019 and based in Malvern, Pennsylvania, Baudax Bio continues to push forward with its mission to develop meaningful therapeutic solutions for acute care settings, drawing on robust clinical research and innovative therapeutic approaches.